Boston Scientific Operating Cash Flow decreased by 74.5% to $348.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 35.7%, from $541.00M to $348.00M. Over 4 years (FY 2021 to FY 2025), Operating Cash Flow shows an upward trend with a 24.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Consistently high operating cash flow indicates a healthy, self-sustaining business capable of funding its own growth and returning capital to shareholders.
Net cash from operating activities measures the total amount of cash generated by a company's core business operations....
Investors often compare this to capital expenditures to calculate Free Cash Flow, a primary valuation metric for mature tech giants.
net_cash_from_operating| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $643.00M | $465.00M | $478.00M | -$58.00M | $307.00M | $470.00M | $807.00M | $190.00M | $658.00M | $698.00M | $957.00M | $164.00M | $813.00M | $1.00B | $1.46B | $541.00M | $1.29B | $1.34B | $1.36B | $348.00M |
| QoQ Change | — | -27.7% | +2.8% | -112.1% | +629.3% | +53.1% | +71.7% | -76.5% | +246.3% | +6.1% | +37.1% | -82.9% | +395.7% | +23.2% | +45.3% | -62.8% | +137.7% | +4.4% | +1.6% | -74.5% |
| YoY Change | — | — | — | — | -52.3% | +1.1% | +68.8% | +427.6% | +114.3% | +48.5% | +18.6% | -13.7% | +23.6% | +43.6% | +52.1% | +229.9% | +58.2% | +34.0% | -6.3% | -35.7% |